Sarepta falls after-hours on FDA accelerated approval guidance
This article was originally published in Scrip
Executive Summary
Sarepta Therapeutics' wild public market ride continues to be bumpy as investors debate whether the US FDA will grant accelerated approval for the company's Duchenne muscular dystrophy (DMD) drug eteplirsen as evidenced by Sarepta's 6.5% decline in after-hours trading on 15 April based on guidance that may cause a delayed early filing.